Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study.

ABSTRACT:

Importance

Erythema multiforme (EM) may become long term, with a recurrent or persistent course. First-line treatment for chronic EM is valaciclovir. There is no consensus for selection of second-line treatment of chronic EM.

Objective

The aim of this study was to assess the effectiveness of treatment with thalidomide for patients with chronic EM.

Design, setting, and participants

In this retrospective national multicenter cohort study, among 68 French hospital dermatology departments contacted by e-mail, 10 reported having eligible cases. All adults aged 18 years or older under dermatology care for chronic EM (including recurrent and persistent forms) who had received thalidomide between 2010 and 2018 were included. Analyses were conducted from June 24, 2019, to Dece

SUBMITTER: Roux C 

PROVIDER: S-EPMC8581790 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature